β-VLDL accumulation in familial dysbetalipoproteinemia is associated with increased exchange or diffusion of chylomicron lipids to apo b-100 containing triglyceride-rich lipoproteins

Atherosclerosis

Volumn 138, Issue 2, 1998, Pages 301-312

  DemacKer, Pierre N m ^a   Bredie, Sebastian J h ^a   Vogelaar, Janine M ^a   Hectors, Magda P c ^a   Van Heijst, Pieternel ^a   M J Stuyt, Paul ^a   Stalenhoef, Anton F h ^a  

^a Division of General Internal Medicine   (Netherlands)

Author keywords

Apolipoprotein B 48; Lipid transfer or diffusion; Lipolysis; Lipoproteins; Postprandial phase

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CHYLOMICRON; RETINOL PALMITATE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL DISEASE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; LIPID DIET; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL;

ADULT; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; CHYLOMICRONS; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; LIPOPROTEINS, VLDL; MIDDLE AGED; TRIGLYCERIDES;

EID: 0032104061     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00035-5     Document Type: Article

References (59)

1. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins. An integrated approach to mechanisms and disorders. N Engl J Med 1967;276:34-44,94-103,148-156,215-226,273-281.
2. Mahley RW, Rall CR Jr, Type III hyperlipoproteinemia (Dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver CR, Beadet AL, Sly WS, Valle D, editors. The Metabolic Basis of Inherited Disease. vol. II, New York: McGraw-Hill, 1995:1953-1980.
3. Kane J.P., Chen G.C., Hamilton R.L., Hardman D.A., Malloy M.J., Havel R.J. Remnants of lipoproteins of intestinal and hepatic origin in familial dysbetalipoproteinemia. Arteriosclerosis. 3:1983;47-56.
4. Fainaru M., Mahley R.W., Hamilton R.L., Innerarity T.L. Structural and metabolic heterogeneity of β-very low density lipoproteins from cholesterol-fed dogs and from humans with type III hyperlipdemia. J Lipid Res. 23:1982;702-714.
5. Mahley R.W., Innerarity T.L. Lipoprotein receptors and cholesterol homeostasis. Biochim Biophys Acta. 737:1983;197-222.
6. Utermann G., Hees M., Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature. 269:1977;604-607.
7. Utermann G., Jaeschke M., Menzel J. Familial hyperlipoproteinemia type III: Deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins. FEBS Lett. 56:1975;352-355.
8. Havel R.J., Chao Y.S., Windler E.E., Kotite L., Guo L.S.S. Isoprotein specificity in the hepatic uptake of apolipoprotein E and the pathogenesis of familial dysbetalipoproteinemia. Proc Natl Acad Sci USA. 77:1980;4349-4353.
9. Schneider W.J., Kovanen P.T., Brown M.S., Goldstein J.L., Utermann G., Weber W., Havel R.J., Kotite L., Kane J.P., Innerarity T.L., Mahley R.W. Familial dysbetalipoproteinemia, abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits and cows. J Clin Invest. 68:1981;1075-1085.
10. Rall S.C. Jr., Weisgraber K.H., Innerarity T.L., Mahley R.W. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci USA. 257:1982;4171.
11. Zannis V.I., Breslow J.L. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry. 20:1981;1033-1041.
12. Zannis V.I., Just P.W., Breslow J.L. Human apolipoproteinE isoprotein subclasses are genetically determined. Am J Hum Genet. 33:1981;11-24.
13. Weisgraber K.H., Rall S.C. Jr., Mahley R.W. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo E isoforms. J Biol Chem. 256:1981;9077-9083.
14. Weisgraber K.H. Apolipoprotein E: Structure-function relationships. Adv Protein Chem. 45:1994;249-302.
15. Cohn J.S., McNamara J.R., Cohn S.D., Ordovas J.M., Schaefer R.J. Plasma apolipoprotein changes in the triglyceride rich lipoproteins fraction of human subjects fed a fat-rich meal. J Lipid Res. 29:1988;925-936.
16. Innerarity T.L., Weisgraber K.H., Arnold K.S., Rall S.C. Jr., Mahley R.W. Normalization of receptor binding of apolipoprotein E-2. Evidence for modulation of the binding site conformation. J Biol Chem. 259:1984;7261-7267.
17. Weisgraber K.H., Rall S.C. Jr., Mahley R.W., Milner R.W., Marcel Y.L., Sparrow J.T. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J Biol Chem. 261:1986;2068-2076.
18. Ji Z.-S., Fazio S., Mahley R.W. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem. 269:1994;13429-13436.
19. Horie Y., Fazio S., Westerlund J.R., Weisgraber K.H., Rall S.C. Jr. The functional characteristics of a human apoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. J Biol Chem. 267:1992;1962-1968.
20. Fazio S., Horie Y., Weisgraber K.H., Havekes L.M., Rall S.C. Jr. Preferential association of apolipoprotein E Leiden with very low density lipoproteins of human plasma. J Lipid Res. 34:1993;447-453.
21. Ehnholm C., Mahley D.W., Chapell D.A., Weisgraber K.H., Ludwig E., Witztum J.L. Role of apoprotein E in the lipolytic conversion of β-VLDL to LDL in type III hyperlipoproteinemia. Proc Natl Acad Sci USA. 81:1984;5566-5570.
22. Chung B.H., Segrest J.P. Resistance of a very low density lipoprotein subpopulation from familial dysbetalipoproteinemics to in vitro lipolytic conversion to the low density lipoprotein fraction. J Lipid Res. 24:1983;1148-1159.
23. Chappell D.A. Pre-β-very low density lipoproteins as precursors of β-very low density lipoproteins: a model for the pathogenesis of familial dysbetalipoproteinemia (type III hyperlipoproteinemia). J Clin Invest. 82:1988;628-639.
24. Tall A., Granot E., Brocia R., Tabas I., Hesler C., Williams K., Denke M. Accelerated transfer of cholesteryl esters in dyslipidemic plasma. Role of cholesteryl esters in dyslipidemic plasma. Role of cholesteryl ester transfer protein. J Clin Invest. 79:1987;1217-1225.
25. McPherson R., Mann C.J., Tall A.R., Hoque M., Williams K., Denke M. Accelerated transfer of cholesteryl esters in dyslipidemic plasma. Role of cholesteryl ester transfer protein. J Clin Invest. 79:1987;1217-1225.
26. Demacker P.N.M., van Heijst P.J., Stalenhoef A.F.H. A study of the chylomicron metabolism in WHHL rabbits after fat loading. Discrepancy between results based on measurement of apoprotein B-48 or retinyl palmitate. Biochem J. 285:1992;641-646.
27. Goodman D.S. Vitamin A and retinoids in health and disease. N Engl J Med. 310:1984;1023-1031.
28. Berr F., Kern F. Plasma clearance of chylomicrons labeled with retinyl palmitate in healthy human subjects. J Lipid Res. 25:1984;805-812.
29. Wilson D.E., Chan I.F., Ball M. Plasma lipoprotein retinoids after vitamin A feeding in normal man: minimal appearance of retinyl esters among low density lipoproteins. Metabolism. 32:1983;514-517.
30. Zilversmit D.B., Morton R.E., Hughes L.B., Haeflein Thompson K. Exchange of retinyl and cholesteryl esters between lipoproteins of rabbit plasma. Biochim Biophys Acta. 712:1982;88-93.
31. Kayden HJ, Traber MG. Transport of vitamin E in human lipoproteins. In: Mino M, Nakamura H, Diplock AT, Kayden HJ, editors. Vitamin E. Its usefulness in health and in curing diseases. Tokyo: Japan Scientific Societies Press, 1993; 85-93.
32. Demacker P.N.M., Reijnen I.G.M., Katan M.B., Stuyt P.M.J., Stalenhoef A.F.H. Increased removal of remnants of triglyceride-rich lipoproteins on a diet rich in polyunsaturated fatty acids. Eur J Clin Invest. 21:1991;197-203.
33. Kuchinskiene Z., Carlson L.A. Composition, concentration and size of low density lipoproteins and of subfractions of very low density lipoproteins from serum of normal men and women. J Lipid Res. 23:1982;762-769.
34. Havel R.J., Eder H.A., Bragdon J.H. The distribution and clinical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 34:1955;1345-1355.
35. Vega GL, Grundy SM. Quantitation of apolipoprotein B by chemical methods. In: Bradley WA, Gianturco SH, Segrest JP, editors. Plasma Lipoproteins, Methods in Enzymology. New York: Academic Press, 263, 1996:63-82.
36. Karpe F., Hamsten A. Determination of apolipoproteins B-48 and B-100 in triglyceride-rich lipoproteins by analytical SDS-PAGE. J Lipid Res. 35:1994;1311-1317.
37. Stalenhoef A.F.H., Malloy M.J., Kane J.P., Havel R.J. Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia. J Clin Invest. 78:1986;722-728.
38. Kotite L., Bergeron N., Havel R.J. Quantification of apolipoproteins B-100, B-48 and E in human triglyceride-rich lipoproteins. J Lipid Res. 361:1995;890-900.
39. Cohn J.S., Johnson E.J., Millar J.S., Cohn D.S., Milne R.V., Marcel Y.L., Russell R.M., Schaefer E.J. Contribution of apo B-48 and apo B-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res. 34:1993;2033-2040.
40. Schneeman B.O., Kotite L., Todd K.M., Havel R.J. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B48 and B100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci USA. 90:1993;2063-2073.
41. Milne R.W., Blanchette L., Theolis R., Weech P.K., Marcel Y.L. Monoclonal antibodies distinguish between lipid-dependent and reversible conformational states of human apolipoprotein B. Mol Immunol. 24:1987;435-447.
42. Brenninkmeijer B.J., Stuyt P.M.J., Demacker P.N.M., Stalenhoef A.F.H. Catabolism of chylomicron remnants in normolipidemic subjects in relation to the apoprotein E phenotype. J Lipid Res. 28:1987;361-370.
43. de Graaf J., Hak-Lemmers H.L.M., Hectors M.P.C., Demacker P.N.M., Hendriks J.C.M., Stalenhoef A.F.H. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb. 11:1991;298-306.
44. Karpe F., Steiner G., Olivercrona T., Carlson L.A., Hamsten A. Metabolism of triglyceride-rich lipoproteins during alimentary lipemia. J Clin Invest. 91:1993;748-748.
45. Traber M.G., Sokol R.J., Burton G.W., Ingold K.U., Papas A.M., Huffaker J.E., Kayden H.J. Impaired ability of patients with familial isolated vitamin E deficiency to incorporate α-tocopherol into lipoproteins secreted by the lever. J Clin Invest. 85:1990;397-407.
46. Traber M.G., Rader D., Acuff R.V., Brewer H.B. Jr., Kayden H.J. Discrimination between RRR- and all-racemic-α-tocopherols labeled with deuterium by patients with abetalipoproteinemia. Atherosclerosis. 108:1994;27-37.
47. Kayden H.J., Traber M.G. Absorption, lipoprotein transport, and regulation of plasma concentrations of vitamin E in humans. J Lipid Res. 34:1993;343-358.
48. Krasinski S.D., Cohn J.S., Schaefer J.S., Russell R.M. Postprandial plasma retinyl ester response is greater in older subjects compared with younger subjects: evidence for delayed plasma clearance of intestinal lipoproteins. J Clin Invest. 85:1990;883-892.
49. Bjornson L.K., Gniewkowski G., Kayden H.J. A comparison of the exchange of α-tocopherol and of free cholesterol between rat plasma lipoproteins and erythrocytes. J Lipid Res. 16:1957;39-53.
50. Kita T., Goldstein J.L., Brown M.S., Watanabe Y., Hornick C.A., Havel R.J. Hepatic uptake of chyomicron remants in WHHL rabbits: A mechanism genetically distinct from the low density lipoprotein receptor. Proc Natl Acad Sci USA. 79:1982;3623-3627.
51. Stuyt P.M.J., Demacker P.N.M., van't Laar A. Long term treatment of type III hyperlipoproteinemia with clofibrate. Atherosclerosis. 40:1981;329-336.
52. Stuyt P.M.J., Demacker P.N.M., van't Laar A. A study of the hypolipidemic effect of estrogen in type III hyperlipoproteinemia. Horm Metab Res. 18:1986;607-610.
53. Connelly P.W., Maguire G.F., Lee M., Alick Little J. Plasma lipoproteins in familial hepatic lipase deficiency. Arteriosclerosis. 10:1990;40-48.
54. Demacker P.N.M., Staels B., Stalenhoef A.F.H., Auwerx J. Increased removal of β-very low density lipoproteins after ethinyl estradiol is associated with increased mRNA levels for hepatic lipase, lipoprotein lipase, and the low density lipoprotein receptor in Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb. 11:1991;1652-1659.
55. Meijer G.W., Demacker P.N.M., van Tol A., Groener J.E.M., van der Palen J.P.G., Stalenhoef A.F.H., van Zutphen L.F.M., Beijnen A.C. Plasma activities of lecithin cholesteryl acyl transferase and cholesterol ester transfer protein activities and post heparin lipases in inbred strains of rabbits hypo- or hyperresponsive to dietary cholesterol. Biochem J. 293:1993;729-734.
56. Ji Z.S., Becht W.J., Miranda R.D., Hussain M.M., Innerarity T.L., Mahley R.W. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem. 268:1993;10160-10167.
57. Mulder M., Lombardi P., Jansen H., van Berkel Th.J.C., Frants R.R., Havekes L.M. Heparin sulphate proteoglycans are involved in the lipoprotein lipase-mediated enhancement of the cellular binding of very low density and low density lipoproteins. Biochem Biophys Res Comm. 185:1992;582-587.
58. Menzel H.J., Kladetzky R.G., Assmann G. Apolipoprotein E polymorphism and coronary heart disease. Arteriosclerosis. 3:1983;310-315.
59. Groot P.H.J., van Stiphout W.A., Kraus X.H., Jansen H., van Tol A., van Ramhorst E., Chin-On S., Hofman A., Cresswell S.R., Havekes L. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary heart disease. Arterioscler Thromb. 11:1991;653-662.